A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Minnelide (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- 02 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
- 19 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 Oct 2016.